Louis B. Nabors
Affiliations: | Neurobiology | University of Alabama, Birmingham, Birmingham, AL, United States |
Area:
Neuroscience Biology, Molecular BiologyGoogle:
"Louis Nabors"Mean distance: 53433
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Bastola S, Pavlyukov MS, Yamashita D, et al. (2020) Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy. Nature Communications. 11: 4660 |
Reardon DA, Desjardins A, Vredenburgh JJ, et al. (2020) Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Lobbous M, Bernstock JD, Coffee E, et al. (2020) An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers. 12 |
Lamb LS, Gibbs S, Pillay T, et al. (2020) Phase I trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified γδ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma multiforme. Journal of Clinical Oncology. 38 |
Romo CG, Alexander BM, Agar N, et al. (2020) Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study. Journal of Clinical Oncology. 38: 2568-2568 |
Lim M, Ye X, Piotrowski AF, et al. (2020) Updated safety phase I trial of anti-LAG-3 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 38: 2512-2512 |
Hayward EN, Yang X, Filippova N, et al. (2020) Abstract 3335: Characterization and analysis of the complement immune system in glioblastoma (GBM) Immunology. 80: 3335-3335 |
Fathallah-Shaykh HM, DeAtkine A, Coffee E, et al. (2019) Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. Plos Medicine. 16: e1002810 |
Kaley T, Nabors LB. (2019) Management of Central Nervous System Tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 579-582 |
Lim M, Ye X, Piotrowski AF, et al. (2019) Updated phase I trial of anti-LAG-3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM. Journal of Clinical Oncology. 37: 2017-2017 |